Eric Suan, MD
Ophthalmology · Baltimore, MDNPI 1275536971
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (31.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 29.8% of the total. Reporting peaked in 2024 at $21,779 and has fallen 82.4% since, to $3,829 in 2025. Among ophthalmology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $164.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$12K
- Genentech USA, Inc.$11K
- Janssen Research & Development, LLC$5K
- Genentech, Inc.$4K
- Eyepoint US, Inc.$3K
- Astellas Pharma US Inc$3K
- plus $3K from 12 others
Across 772 payments — averaging $8858.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3.1M
- Genentech, Inc.$2.8M
- Bayer$409K
- Apellis Pharmaceuticals, Inc.$306K
- Regeneron$94K
- Eyepoint US, Inc.$60K
- plus $73K from 3 others
What the payments were for
- Consulting fees$12,73732%
- Speaking & faculty fees$9,66524%
- Travel & lodging$8,26521%
- Food & beverage$9,38023%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 72 | $11,937 |
| Genentech USA, Inc. | 44 | $11,320 |
| Janssen Research & Development, LLC | 19 | $4,855 |
| Genentech, Inc. | 6 | $3,531 |
| Eyepoint US, Inc. | 13 | $2,764 |
| Astellas Pharma US Inc | 7 | $2,559 |
| Apellis Pharmaceuticals, Inc. | 20 | $916 |
| AbbVie(2 entities) | 31 | $839 |
| Novartis | 8 | $413 |
| Regeneron | 3 | $397 |
| Alimera Sciences, Inc. | 8 | $167 |
| Coherus Oncology, Inc. | 3 | $92 |
| Bausch & Lomb Americas Inc. | 4 | $78 |
| Alcon | 1 | $66 |
| Sandoz | 2 | $63 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Spark Therapeutics, Inc. | 1 | $12 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,047 in reported general payments places this provider in the 90th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 55 | $2,331 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 23 | $107 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Baltimore
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Neil BresslerBaltimore$265K
- Adrienne ScottBaltimore$170K
- Jennifer ThorneBaltimore$128K
- Earl CravenBaltimore$120K
- Peter CampochiaroBaltimore$103K
- Gail SchwartzBaltimore$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.